Moderate Evidence
Research Overview
Oveporexton Research for Excessive Daytime Sleepiness
An overview of research and source records on Oveporexton in the context of excessive daytime sleepiness.
Research Summary
In TAK-861-2001 the primary endpoint (MWT sleep latency) improved significantly, and ESS (secondary) was also significantly reduced. Oveporexton promotes wakefulness through direct OX2R activation in arousal centers, addressing the underlying orexin deficiency.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.